---
title: Prevalence of Neuropsychiatric Manifestations in IBD Patients in Upper Egypt
nct_id: NCT04573400
overall_status: UNKNOWN
sponsor: Assiut University
study_type: OBSERVATIONAL
primary_condition: IBD
canonical_url: "https://parkinsonspathways.com/agent/trials/NCT04573400.md"
clinicaltrials_gov: "https://clinicaltrials.gov/study/NCT04573400"
ct_last_update_post_date: 2020-10-05
last_seen_at: "2026-05-12T06:32:26.585Z"
source: ClinicalTrials.gov (mirrored, no enrichment)
---
# Prevalence of Neuropsychiatric Manifestations in IBD Patients in Upper Egypt

**NCT ID:** [NCT04573400](https://clinicaltrials.gov/study/NCT04573400)

## Key Facts

- **Status:** UNKNOWN
- **Study Type:** OBSERVATIONAL
- **Target Enrollment:** 90
- **Lead Sponsor:** Assiut University
- **Conditions:** IBD
- **Start Date:** 2021-01-01
- **Completion Date:** 2022-05-01
- **CT.gov Last Update:** 2020-10-05

## Brief Summary

Estimation of neuropsychiatric symptoms prevalence in IBD patients and their impact on quality of life.

## Detailed Description

Crohn's disease (CD) and ulcerative colitis (UC) are the two main types of idiopathic inflammatory bowel disease (IBD), clearly distinct pathophysiological entities. UC, the most common form of IBD worldwide, is a disease of the colonic mucosa only; it is less prone to complications. In contrast, CD is a transmural disease of the gastrointestinal mucosa which can affect the entire gastrointestinal tract . CD and UC should be considered systemic diseases since they are associated with clinical manifestations involving organs outside the alimentary tract. Extraintestinal manifestations involve several organs, and either precede the onset of intestinal manifestations or appear and evolve in parallel with them . Neurologic involvement associated with IBD is frequently underreported. Nevertheless, it is important to quantify the morbidity burden of clinically significant neurologic complications in IBD because early recognition and treatment of neurologic diseases are crucial for preventing major morbidity . Neurologic involvement in IBD as a subgroup of the EIMs may precede the appearance of digestive symptoms or develop after diagnosis of IBD. In addition, neurological symptoms may exacerbate during flare-ups of IBD or evolve independently from intestinal manifestations without responding to treatment provided for the underlying bowel disease.Within (IBD) literature, anxiety and depression symptoms are commonly identified to be associated with increased disease activity and reduced quality of life. Research also indicates that ongoing psychological distress can exacerbate disease activity,\] and increase the risk of flare-ups and health care costs. Given this, screening and targeted treatment of neuropsychological conditions in IBD patients are crucial.

## Eligibility

- **Minimum age:** 18 Years
- **Sex:** ALL
- **Healthy Volunteers:** No

```
Inclusion Criteria:

* patients under the care of the hospital IBD outpatient service and having been diagnosed with IBD, aged over 18 years, and able to complete the examination and questionnaire.

Exclusion Criteria:

* Patients under the age of 18.
```

## Interventions

- **HADS** (OTHER) — The HADS is a 14-item self-report questionnaire assessing levels of anxiety (seven items) and depression (seven items) over the past week. Each question is assessed on a 4-point Likert Scale: "I feel tense or 'wound up'" (0= not at all 3= most of the time). Consistent with recommendations by Bjelland et al cut-off of 8 for each HADS subscale will be used to differentiate normal from mild to severe distress.

## Primary Outcomes

- **Identify prevalence of neurological and psychological conditions associated with IBD.** _(time frame: 2021-2022)_

## Recent Field Changes (last 30 days)

- `status.overallStatus` — added _(2026-05-12)_
- `status.primaryCompletionDate` — added _(2026-05-12)_
- `status.completionDate` — added _(2026-05-12)_
- `status.lastUpdatePostDate` — added _(2026-05-12)_
- `design.enrollmentCount` — added _(2026-05-12)_
- `eligibility.criteria` — added _(2026-05-12)_
- `eligibility.minAge` — added _(2026-05-12)_
- `eligibility.sex` — added _(2026-05-12)_
- `outcomes.primary` — added _(2026-05-12)_
- `armsInterventions.interventions` — added _(2026-05-12)_
- `sponsor.lead` — added _(2026-05-12)_
- `results.hasResults` — added _(2026-05-12)_

---

*Canonical: https://parkinsonspathways.com/agent/trials/NCT04573400.md*  
*Source data (authoritative): https://clinicaltrials.gov/study/NCT04573400*  
*This page is a raw mirror with no AI summary, no editorial enrichment, and no Parkinson's-specific filtering.*